---
title: "Theravance BioPharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 17.7 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285553665.md"
datetime: "2026-05-07T12:40:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285553665.md)
  - [en](https://longbridge.com/en/news/285553665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285553665.md)
---

# Theravance BioPharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 17.7 M

Revenue: As of FY2026 Q1, the actual value is USD 17.7 M, beating the estimate of USD 17.45 M.

EPS: As of FY2026 Q1, the actual value is USD -0.1, missing the estimate of USD 0.028.

EBIT: As of FY2026 Q1, the actual value is USD -12.5 M.

#### Financial and Operational Metrics

Based on the provided reference, the actual financial results, operational metrics, or outlook/guidance details for Theravance Biopharma, Inc. (Theravance 生物制药) for the quarter ended March 31, 2026, are not included within the text for extraction. The reference only indicates that a press release regarding these results was issued on May 7, 2026, as part of a Form 8-K filing .

### Related Stocks

- [TBPH.US](https://longbridge.com/en/quote/TBPH.US.md)

## Related News & Research

- [Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update | TBPH Stock News](https://longbridge.com/en/news/285551659.md)
- [Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | TBPH Stock News](https://longbridge.com/en/news/279788810.md)
- [Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors | IMUX Stock News](https://longbridge.com/en/news/286894992.md)
- [JD Vance Gives Head-Turning Answer On How That Slush Fund Will Be Used](https://longbridge.com/en/news/287018621.md)
- [This Baby Name Is Tanking In Popularity. Are Politics To Blame?](https://longbridge.com/en/news/287208182.md)